[go: up one dir, main page]

WO2008003855A3 - Utilisation de 2-benzoyl-imidazopyridines en thérapeutique - Google Patents

Utilisation de 2-benzoyl-imidazopyridines en thérapeutique Download PDF

Info

Publication number
WO2008003855A3
WO2008003855A3 PCT/FR2007/001124 FR2007001124W WO2008003855A3 WO 2008003855 A3 WO2008003855 A3 WO 2008003855A3 FR 2007001124 W FR2007001124 W FR 2007001124W WO 2008003855 A3 WO2008003855 A3 WO 2008003855A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogens
chlorophenyl
phenyl
methyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/001124
Other languages
English (en)
Other versions
WO2008003855A2 (fr
Inventor
Jean-Francois Peyronel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07803832A priority Critical patent/EP2040705A2/fr
Priority to AU2007271083A priority patent/AU2007271083A1/en
Priority to CA002655552A priority patent/CA2655552A1/fr
Priority to MX2008016560A priority patent/MX2008016560A/es
Priority to BRPI0714318-4A2A priority patent/BRPI0714318A2/pt
Priority to JP2009517331A priority patent/JP2009541470A/ja
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of WO2008003855A2 publication Critical patent/WO2008003855A2/fr
Publication of WO2008003855A3 publication Critical patent/WO2008003855A3/fr
Priority to IL195817A priority patent/IL195817A0/en
Priority to US12/336,998 priority patent/US20090143421A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne l'utilisation en thérapeutique des dérivés de formule générale (I): X est un phényle, R1, R2, R3 et R4 sont des hydrogènes; ou X est un phényle, R3 est méthyle et R1, R2 et R4 sont des hydrogènes; ou X est un phényle, R2 est chlore ou méthoxy et R1, R3 et R4 sont des hydrogènes; ou X est un phényle, R2 et R3 sont méthoxy et R1 et R4 sont des hydrogènes; ou X est un phényle, R1 est méthoxy et R2, R3 et R4 sont des hydrogènes; ou X est un phényle, R3 est méthoxy et R1, R2 et R4 sont des hydrogènes; ou X est un 4-méthylphényle, R2 est un méthyle et R1, R3 et R4 sont des hydrogènes; ou X est un 4-chlorophényle, R1 est un chlore ou un méthoxy ou un méthyle, et R2, R3 et R4 sont des hydrogènes; ou X est un 4-chlorophényle, R2 est un chlore ou un méthyle et R1, R3 et R4 sont des, hydrogènes; ou X est un 4-chlorophényle, R3 est un méthyle, et R1, R2 et R3 sont des hydrogènes; ou X est un 4-chlorophényle, R4 est un méthyle et R1, R2 et R4 sont des hydrogènes; ou X est un 4-chlorophényle, R1 et R3 sont des méthyles et R2 et R4 sont des hydrogènes, ou X est un 4-chlorophényle et R1, R2, R3 et R4 sont des hydrogènes, ou X est un 2-chlorophényle et R1, R2, R3 et R4 sont des hydrogènes, ou X est un 4-méthylphényle et R1, R2, R3 et R4 sont des hydrogènes, à l'état de base ou de sel d'addition à un acide.
PCT/FR2007/001124 2006-07-03 2007-07-03 Utilisation de 2-benzoyl-imidazopyridines en thérapeutique Ceased WO2008003855A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2007271083A AU2007271083A1 (en) 2006-07-03 2007-07-03 Use of 2-benzoyl-imidazopyridines in therapeutics
CA002655552A CA2655552A1 (fr) 2006-07-03 2007-07-03 Utilisation de 2-benzoyl-imidazopyridines en therapeutique
MX2008016560A MX2008016560A (es) 2006-07-03 2007-07-03 Utilizacion de 2-benzoil-imidazopiridinas en terapeutica.
BRPI0714318-4A2A BRPI0714318A2 (pt) 2006-07-03 2007-07-03 Utilização de 2-benzoil-imidazopiridinas em terapêutica
JP2009517331A JP2009541470A (ja) 2006-07-03 2007-07-03 療法における２−ベンゾイル−イミダゾピリジンの使用
EP07803832A EP2040705A2 (fr) 2006-07-03 2007-07-03 Utilisation de 2-benzoyl-imidazopyridines en thérapeutique
IL195817A IL195817A0 (en) 2006-07-03 2008-12-09 Use of 2-benzoyl-imidazopyridines in therapeutics
US12/336,998 US20090143421A1 (en) 2006-07-03 2008-12-17 Use of 2-benzoyl-imidazopyridines in therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606011 2006-07-03
FR0606011A FR2903106B1 (fr) 2006-07-03 2006-07-03 Utilisations de 2-benzoyl-imidazopyridines en therapeutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/336,998 Continuation US20090143421A1 (en) 2006-07-03 2008-12-17 Use of 2-benzoyl-imidazopyridines in therapeutics

Publications (2)

Publication Number Publication Date
WO2008003855A2 WO2008003855A2 (fr) 2008-01-10
WO2008003855A3 true WO2008003855A3 (fr) 2008-03-06

Family

ID=37781864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001124 Ceased WO2008003855A2 (fr) 2006-07-03 2007-07-03 Utilisation de 2-benzoyl-imidazopyridines en thérapeutique

Country Status (13)

Country Link
US (1) US20090143421A1 (fr)
EP (1) EP2040705A2 (fr)
JP (1) JP2009541470A (fr)
KR (1) KR20090033863A (fr)
CN (1) CN101484164A (fr)
AU (1) AU2007271083A1 (fr)
BR (1) BRPI0714318A2 (fr)
CA (1) CA2655552A1 (fr)
FR (1) FR2903106B1 (fr)
IL (1) IL195817A0 (fr)
MX (1) MX2008016560A (fr)
RU (1) RU2009103321A (fr)
WO (1) WO2008003855A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925903B1 (fr) * 2008-01-02 2011-01-21 Sanofi Aventis DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2933609B1 (fr) 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638161A1 (fr) * 1988-10-24 1990-04-27 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501411A (ja) * 1995-12-05 2000-02-08 ダーウィン・ディスカバリー・リミテッド ベンゾフランカルボキサミドおよびスルホンアミド
CA2521907A1 (fr) * 2003-04-10 2004-10-21 Pfizer Inc. Composes bicycliques comme antagonistes du recepteur nr2b
US20060040298A1 (en) * 2004-08-05 2006-02-23 Azriel Schmidt Rhesus monkey NURR1 nuclear receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638161A1 (fr) * 1988-10-24 1990-04-27 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRASSY GERARD ET AL: "Inhibitory effects on platelet aggregation and cyclic AMP phosphodiesterase of azainodolizine-type compounds: Structure-activity relationships and molecular modelling", CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, vol. 20, no. 1, 1993, pages 71 - 84, XP002424196, ISSN: 0169-7439 *
SCHMITT M ET AL: "IMIDAZO1,2-B)PYRIDAZINES. XXIII SOME 5-DEAZA ANALOGUES. SYNTHESES OF SOME 2-ARYL-6-(CHLORO, METHOXY OR UNSUBSTITUTED)-3- (VARIOUSLY SUBSTITUTED)IMIDAZO1,2-APYRIDINES AND THEIR AFFINITY FOR CENTRAL AND MITOCHONDRIAL BENZODIAZEPINE RECEPTORS", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 50, no. 7, 1997, pages 719 - 725, XP001010372, ISSN: 0004-9425 *
THEUNS J ET AL: "O4-06-03 A novel NR4A2 promoter variation associated with Parkinson's disease alters gene expression", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 25, July 2004 (2004-07-01), pages S85, XP004624904, ISSN: 0197-4580 *

Also Published As

Publication number Publication date
KR20090033863A (ko) 2009-04-06
RU2009103321A (ru) 2010-08-10
FR2903106B1 (fr) 2010-07-30
EP2040705A2 (fr) 2009-04-01
FR2903106A1 (fr) 2008-01-04
CA2655552A1 (fr) 2008-01-10
MX2008016560A (es) 2009-01-19
CN101484164A (zh) 2009-07-15
US20090143421A1 (en) 2009-06-04
JP2009541470A (ja) 2009-11-26
IL195817A0 (en) 2009-09-01
BRPI0714318A2 (pt) 2014-06-24
AU2007271083A1 (en) 2008-01-10
WO2008003855A2 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
TW200833324A (en) Sulfonamide derivatives
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
NO20071593L (no) Pyrimidinderivater
WO2007048064A3 (fr) Aminopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
DK2074120T3 (da) Tropan-forbindelser
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
BRPI1013932A2 (pt) "derivados de 7-aza-espiro [3.5]nonano-7- carboxilatos, o respectivo preparo e a respectiva aplicação em terapêutica"
WO2008003855A3 (fr) Utilisation de 2-benzoyl-imidazopyridines en thérapeutique
TW200531683A (en) Aryl- and heteroarylpiperidinecarboxylate derivatives, their preparation and their application in therapeutics
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
MA32579B1 (fr) Derives de carbamates d'alkylthiazoles, leur preparation et leur utilisation comme inhbiteurs de l'enzyme faah
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
WO2007099171A3 (fr) Bicyclopyrazoles actifs comme inhibiteurs de la kinase
NO20070089L (no) DPP-IV inhibitorer
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
NO20084177L (no) Substituerte Imidazo[2,1-B]thiazolforbindelser og deres anvendelse for produksjon av legemidler
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
WO2009106750A3 (fr) Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
GB0602951D0 (en) Organic Compounds
WO2007020411A8 (fr) Dérivés amide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780025168.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803832

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 195817

Country of ref document: IL

Ref document number: 2007803832

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5100/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2655552

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007271083

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/016560

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009517331

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097000040

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007271083

Country of ref document: AU

Date of ref document: 20070703

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009103321

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714318

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090102